{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:04:09Z","timestamp":1789560249557,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jval.2026.06.024","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:29:01Z","timestamp":1786663741000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Epigenetic Drugs in Oncology: A Systematic Review of Economic Evaluations"],"prefix":"10.1016","author":[{"given":"Lou-Anne","family":"Peretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-021-01069-7","article-title":"Advances in epigenetic therapeutics with focus on solid tumors","volume":"13","author":"Jin","year":"2021","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jval.2026.06.024_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.jval.2026.06.024_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1017\/S0266462318000636","article-title":"Which databases should be used to identify studies for systematic reviews of economic evaluations?","volume":"34","author":"Arber","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"10.1016\/j.jval.2026.06.024_bib6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J Med Libr Assoc"},{"issue":"2","key":"10.1016\/j.jval.2026.06.024_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jval.2014.01.003","article-title":"Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report","volume":"17","author":"Jaime Caro","year":"2014","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.06.024_bib8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","article-title":"Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report","volume":"19","author":"Wolowacz","year":"2016","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2026.06.024_bib9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task Force\u20132","volume":"32","author":"Roberts","year":"2012","journal-title":"Med Decis Mak"},{"issue":"3","key":"10.1016\/j.jval.2026.06.024_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40273-022-01232-9","article-title":"Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment","volume":"41","author":"Lu","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2026.06.024_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2026.06.024_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jval.2023.05.011","article-title":"Economic evaluations of guideline-directed medical therapies for heart failure with reduced ejection fraction: a systematic review","volume":"26","author":"Kuan","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR Cheers II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.06.024_bib14","first-page":"8656","article-title":"A systematic review and quality assessment of pharmacoeconomic publications for China compared to internationally: is the quality of evidence-base sufficient for health technology assessment?","volume":"14","author":"Fan","year":"2025","journal-title":"Int J Health Policy Manag"},{"key":"10.1016\/j.jval.2026.06.024_bib15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/CEOR.S559471","article-title":"Cost-utility analyses of hemodialysis, peritoneal dialysis, and kidney transplantation in patients with end-stage kidney disease: a systematic review","volume":"17","author":"Wulandari","year":"2025","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3111\/13696998.2011.631067","article-title":"A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes","volume":"15","author":"Gidwani","year":"2012","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.jval.2026.06.024_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3497","article-title":"Cost-effectiveness of novel treatment sequences for transplant-ineligible patients with multiple myeloma","volume":"4","author":"Blommestein","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.06.024_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3310\/hta14Suppl1-10","article-title":"Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia","volume":"14","author":"Edlin","year":"2010","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib22","article-title":"Cost-effectiveness of azacitidine compared with low doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)","volume":"4","author":"Candelaria Hern\u00e1ndez","year":"2017","journal-title":"Glob Reg Health Technol Assess"},{"issue":"5","key":"10.1016\/j.jval.2026.06.024_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-021-01098-3","article-title":"Mogamulizumab for previously treated mycosis fungoides and S\u00e9zary syndrome: an evidence review group perspective of a NICE single technology appraisal","volume":"40","author":"Grimm","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2026.06.024_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/10428194.2022.2140288","article-title":"Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia","volume":"64","author":"Bewersdorf","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib25","first-page":"29","article-title":"Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States","volume":"24","author":"Carlson","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2191-1991-3-28","article-title":"Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain","volume":"3","author":"Crespo","year":"2013","journal-title":"Health Econ Rev"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/13696998.2024.2352820","article-title":"Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States","volume":"27","author":"Matasar","year":"2024","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.jval.2026.06.024_bib28","first-page":"1","article-title":"Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2- mutant refractory\/relapsed AML","volume":"66","author":"Alhajahjeh","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jval.2026.06.024_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s41669-019-00180-z","article-title":"Economic evaluation of azacitidine in elderly patients with acute myeloid leukemia with high Blast Counts","volume":"4","author":"Coyle","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"4","key":"10.1016\/j.jval.2026.06.024_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/17474086.2022.2061456","article-title":"Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia","volume":"15","author":"Zhu","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12885-024-12362-y","article-title":"Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.jval.2026.06.024_bib32","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.clinthera.2010.12.003","article-title":"Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective","volume":"32","author":"Pan","year":"2010","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib33","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3747\/co.21.1311","article-title":"Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes","volume":"21","author":"Levy","year":"2014","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/13696998.2021.1875743","article-title":"The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada","volume":"24","author":"Hu","year":"2021","journal-title":"J Med Econ"},{"issue":"8","key":"10.1016\/j.jval.2026.06.024_bib35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40273-022-01145-7","article-title":"Cost-effectiveness analysis of venetoclax in combination with azacitidine versus azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: from a US third party payer perspective","volume":"40","author":"Pratz","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2026.06.024_bib36","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jval.2026.06.024_bib37","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.3390\/curroncol29100592","article-title":"Venetoclax in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia: a Canadian cost\u2013utility analysis","volume":"29","author":"Guinan","year":"2022","journal-title":"Curr Oncol"},{"issue":"22","key":"10.1016\/j.jval.2026.06.024_bib38","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/bloodadvances.2021005472","article-title":"Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia","volume":"5","author":"Bewersdorf","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jval.2026.06.024_bib40","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40273-024-01413-8","article-title":"Systematic review of economic evaluations of systemic treatments for advanced and metastatic gastric cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"22","key":"10.1016\/j.jval.2026.06.024_bib41","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.3390\/cancers13225606","article-title":"A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma","volume":"13","author":"Seefat","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.jval.2026.06.024_bib42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40258-019-00513-3","article-title":"A review of recent decision-analytic models used to evaluate the economic value of cancer treatments","volume":"17","author":"Bullement","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"issue":"8","key":"10.1016\/j.jval.2026.06.024_bib44","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jval.2024.04.004","article-title":"Economic evaluations of chimeric antigen receptor T-cell therapies for hematologic and solid malignancies: a systematic review","volume":"27","author":"Thavorn","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1471-2466-14-192","article-title":"A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)","volume":"14","author":"Lange","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.jval.2026.06.024_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40273-018-0711-9","article-title":"Trusting the results of model-based economic analyses: is there a pragmatic validation solution?","volume":"37","author":"Ghabri","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2026.06.024_bib48","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.clml.2018.02.005","article-title":"Azacitidine use for myeloid neoplasms","volume":"18","author":"El Fakih","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jval.2026.06.024_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069573","article-title":"Industry sponsorship bias in cost effectiveness analysis: registry based analysis","volume":"377","author":"Xie","year":"2022","journal-title":"BMJ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:18:03Z","timestamp":1789557483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["S1098301526025659"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.024","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Epigenetic Drugs in Oncology: A Systematic Review of Economic Evaluations","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}